Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth CorpfiledCriticalWyeth Corp
Priority to UY25962ApriorityCriticalpatent/UY25962A1/en
Publication of UY25962A1publicationCriticalpatent/UY25962A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Formulaciones de rapamicina que comprende un núcleo y una película azucarada, cuya película azucarada contiene: (a) rapamicina en cantidades aproximadas entre 0,05-20mg. (b) poloxamero 188 en cantidades aproximadas entre 0,008-10mg y (c) sucrosa o sacarosa en cantidades que contienen hasta alrededor de 40-99% del peso de la pelicula azucaradaRapamycin formulations comprising a core and a sugary film, the sugary film of which contains: (a) rapamycin in amounts of approximately 0.05-20mg. (b) poloxamer 188 in amounts of approximately 0.008-10mg and (c) sucrose or sucrose in amounts containing up to about 40-99% of the weight of the sugary film
UY25962A2000-01-172000-01-17
RAPAMICINE FORMULATIONS FOR ORAL ADMINISTRATION
UY25962A1
(en)